Study finds estrogen therapy reduces Alzheimer's risk in women by 39%

Women who underwent estrogen-only hormone therapy later in life showed a significant reduction in the likelihood of developing dementia, according to a major study involving over 21,000 participants. The research indicated that these women had 39% lower odds of receiving a dementia diagnosis and 35% lower odds of exhibiting Alzheimer’s-related changes in their brains at autopsy, including the presence of amyloid plaques and tau tangles.

This study comes at a time when the understanding of menopause and its long-term health impacts is gaining attention. Recent discussions have highlighted the potential benefits and risks of hormone replacement therapies. As more women reach menopause and seek ways to manage its symptoms, studies like this provide crucial insights into the broader implications of hormone therapies on cognitive health.

Participants who used estrogen-only hormone therapy demonstrated lower levels of harmful amyloid buildup, according to biomarker tests. These findings suggest that hormone therapy could play a role in reducing the biological markers associated with Alzheimer’s disease. The results have drawn interest from both medical professionals and patients, prompting discussions about the safety and efficacy of estrogen therapy in aging women.

Looking ahead, this research may influence treatment options for women approaching menopause. If further studies confirm these findings, hormone therapy could be recommended not just for symptom relief but also as a preventive measure against dementia and Alzheimer’s. The implications for public health are significant, as effective preventive strategies could alleviate the growing burden of cognitive decline in an aging population.